- Combination of nivolumab and cabozantinib found to significantly improve progression-free survival and reduced the risk of death versus sunitinib in previously untreated patients with advanced kidney cancer
San Francisco, CA (UroToday.com) — An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.